




GiE

Gatherings in Esophagology
Royaumont Abbey




This program was only made possible thanks to the interest shown by our partners in the Industry



The **GiE** is a new and original initiative from OESO.

For 36 hours, specialists of the highest level will meet in one room to listen to and discuss 36 presentations on a single topic.

This 36 hour (2 nights) event will offer an experience which will foster exchanges and interaction among a group of KOLs (key opinion leaders), in an informal country setting, the “Abbaye de Royaumont”, a 13th Century Cistercian Abbey located in the heart of a forest, only 29 km from Paris.



May 30 and 31, 2025

To our knowledge, this will be a first-of-its-kind event.

We are looking forward to welcoming you to this event.

For further information, please contact: michele.liegeon@oeso.org

DAY 1	02:30 – 3:00 pm	Welcome: John O. Clarke (Stanford, USA) President OESO-SEMPIRE Introduction to the novel format. Robert Giuli (France)
	03:00 – 4:30 pm	Session 1: Current and novel diagnostics <i>Chairs:</i> Walter Chan (USA) – Prakash Gyawali (USA) – Chat session panel (10 minutes) – Questions (5 minutes each) 1. Esophageal Motility Disorders related to GERD. Mark Fox (Switzerland) 2. Non-invasive markers for reflux diagnosis (salivary biomarkers). Rachel Rosen (USA) 3. Catheter-based vs. wireless reflux monitoring. Luis Valdovinos Garcia (Mexico) 4. Provocative maneuvers and scoring systems predictive of GERD. Stefano Siboni (Italy) 5. How to diagnose EGJ disruption and hiatus hernia (Hill vs AFS grade). John O. Clarke (USA) 6. <i>Innovation: Development and assessment of a daily reflux symptom diary as a fit-for-purpose clinical outcomes assessment tool to assess LPR symptom severity and its treatment response.</i> Tina Samuels (USA) • Discussion (50 minutes)
	<i>Break</i>	
	05:00 – 6:30 pm	Session 2: Leveraging new acid suppressants in reflux management <i>Chairs:</i> Adriana Lazarescu (Canada) – Kristle Lynch (USA) – Chat session panel (10 minutes) – Questions (5 minutes each) 1. P-CABs: a new avenue in acid suppression. Carmelo Scarpignato (Italy) 2. Optimizing PPI and H2RA use in reflux disease. Ellen M. Stein (USA) 3. When to consider PCABs in reflux management. Ronnie Fass (USA) 4. Safety profile and side effects of acid suppressants. Jose Remes-Troche (Mexico) 5. On demand vs. daily acid suppressants: when and which agents. Abe Khan (USA) 6. <i>Innovation: GERD symptom prompts: the role for in office vs. at home assessment of disease severity.</i> Afrin Kamal (USA) • Discussion (50 minutes)
<i>Dinner</i>		
DAY 2	<i>Breakfast</i>	
	09:00 – 10:30 am	Session 3: Adjunctive medical management: Mucosal protectants, Reflux reducers, Neuromodulators <i>Chairs:</i> Marcelo Vela (USA) – Justin Wu (Hong Kong) – Chat session panel (10 minutes) – Questions (5 minutes each) 1. Behavioral and lifestyle approaches. Kristle Lynch (USA) 2. Reflux reducing agents (baclofen, bethanechol, others). Daniela Jodorkovsky (USA) 3. Mucosal protective compounds for treatment of GERD. Marcelo Vela (USA) 4. The status of pepsin inhibitors for PPI refractory GERD and LPR. Alexander Lesnick (USA) 5. When are neuromodulators needed in symptomatic reflux disease. Braden Kuo (USA) 6. <i>Innovation: What are the roles of sodium alginates and amprenavir against pepsin-mediated esophageal and laryngeal damage?</i> Pelin Ergun (USA) • Discussion (50 minutes)
<i>Break</i>		

11:00 am – 12:30 pm

Session 4: Advances in invasive reflux management

Chairs: Stefano Siboni (Italy) – Edoardo Savarino (Italy)

– Chat session panel (10 minutes) – Questions (5 minutes each)

1. TIF and C-TIF. Sigh Jirapinyo (USA)
2. Magnetic sphincter augmentation. Emanuele Asti (Italy)
3. Reflux stop. Salvatore Tolone (Italy)
4. Bariatric approaches to managing reflux disease. Eric Sheu (USA)
5. Complications of invasive anti-reflux therapy. Renato Salvador (Italy)
6. *Innovation: Evaluation of the esophagogastric junction barrier before and after intervention.* Marco Sozzi (Italy)
- Discussion (50 minutes)

Lunch

02:00 – 03:30 pm

Session 5: Role of reflux in extra-esophageal syndromes

Chairs: Daniel Sifrim (UK) – Nikki Johnston (USA)

– Chat session panel (10 minutes) – Questions (5 minutes each)

1. How is pharyngeal reflux diagnosed? Inna Husain (USA)
2. Laryngo-pharyngeal symptoms and Laryngopharyngeal reflux disease. Justin Wu (Hong Kong)
3. Reflux and voice disorders. Anthony Hobson (UK)
4. Reflux and pulmonary disease. Nirmal Sharma (USA)
5. Reflux and lung transplant outcomes. Wai-Kit Lo (USA)
6. *Innovation: Reflux vs oropharyngeal dysphagia in pediatric aerodigestive disease.* Daniel Duncan (USA)
- Discussion (50 minutes)

Break

04:00 – 05:30 pm

Session 6: Modern diagnosis of esophageal and laryngeal reflux syndromes

Chairs: Rachel Rosen (USA) – Ronnie Fass (USA)

– Chat session panel (10 minutes) – Questions (5 minutes each)

1. Modern diagnosis of GERD: Lyon Consensus 2.0. Prakash Gyawali (USA)
2. Modern diagnosis of LPRD. Walter Chan (USA)
3. Behavioral syndromes in the evaluation of GERD (belching disorders, rumination). Daniel Sifrim (UK)
4. Mucosal impedance measurements in diagnosing and phenotyping reflux. Edoardo Savarino (Italy)
5. Role of endoscopy in reflux diagnosis. Nicola de Bortoli (Italy)
6. *Innovation: Artificial intelligence for diagnosis of supragastric belching on pH-impedance.* Benjamin Rogers (USA)
- Discussion (50 minutes)

Break

05:45 – 06:30 pm

Wrap-up Session

Dinner

